CytoSorb removes MDMA in vitro, but is it an effective therapy in vivo?

3,4-Methylenedioxymethamphetamine CytoSorb Hemoperfusion Intoxication

Journal

Intensive care medicine experimental
ISSN: 2197-425X
Titre abrégé: Intensive Care Med Exp
Pays: Germany
ID NLM: 101645149

Informations de publication

Date de publication:
29 Jul 2020
Historique:
received: 28 06 2020
accepted: 22 07 2020
entrez: 31 7 2020
pubmed: 31 7 2020
medline: 31 7 2020
Statut: epublish

Résumé

3,4-Methylenedioxymethamphetamine intoxication can result in potentially lethal multi-organ failure, for which the current treatment is largely supportive. Recently, a report of the use of the CytoSorb device as a part of the successful treatment of a patient with 3,4-methylenedioxymethamphetamine intoxication and multi-organ failure has been described. While 3,4-methylenedioxymethamphetamine was very effectively removed by CytoSorb in vitro, the degree of removal in the clinical setting described may have been minimal. Indeed, the therapy was started relatively late in this case, and, as the therapy is concentration dependent, the removal of 3,4-methylenedioxymethamphetamine is likely to have been limited. On the other hand, in this case, CytoSorb hemoadsorption was very effective to treat rhabdomyolysis and hyperinflammation. The in vitro experimentation demonstrates that 3,4-methylenedioxymethamphetamine is effectively removed by CytoSorb. However, it is debatable whether the case report confirms the possibility of in vivo removal of 3,4-methylenedioxymethamphetamine by CytoSorb. Nevertheless, the potential of the CytoSorb device to contribute to the treatment of many critically ill patients has yet to be fully explored, and further studies are warranted.

Sections du résumé

BACKGROUND BACKGROUND
3,4-Methylenedioxymethamphetamine intoxication can result in potentially lethal multi-organ failure, for which the current treatment is largely supportive. Recently, a report of the use of the CytoSorb device as a part of the successful treatment of a patient with 3,4-methylenedioxymethamphetamine intoxication and multi-organ failure has been described.
MAIN BODY METHODS
While 3,4-methylenedioxymethamphetamine was very effectively removed by CytoSorb in vitro, the degree of removal in the clinical setting described may have been minimal. Indeed, the therapy was started relatively late in this case, and, as the therapy is concentration dependent, the removal of 3,4-methylenedioxymethamphetamine is likely to have been limited. On the other hand, in this case, CytoSorb hemoadsorption was very effective to treat rhabdomyolysis and hyperinflammation.
CONCLUSION CONCLUSIONS
The in vitro experimentation demonstrates that 3,4-methylenedioxymethamphetamine is effectively removed by CytoSorb. However, it is debatable whether the case report confirms the possibility of in vivo removal of 3,4-methylenedioxymethamphetamine by CytoSorb. Nevertheless, the potential of the CytoSorb device to contribute to the treatment of many critically ill patients has yet to be fully explored, and further studies are warranted.

Identifiants

pubmed: 32728974
doi: 10.1186/s40635-020-00333-z
pii: 10.1186/s40635-020-00333-z
pmc: PMC7391451
doi:

Types de publication

Letter

Langues

eng

Pagination

38

Références

Blood Purif. 2002;20(4):380-8
pubmed: 12169849
Ther Drug Monit. 2008 Jun;30(3):320-32
pubmed: 18520604
Blood Purif. 2019;48(3):196-202
pubmed: 31039564
CMAJ. 2001 Oct 2;165(7):917-28
pubmed: 11599334
Intensive Care Med Exp. 2020 Jun 15;8(1):21
pubmed: 32542550

Auteurs

Patrick M Honore (PM)

ICU Department, Brugmann University Hospital, Centre Hospitalier Universitaire Brugmann, Place Van Gehuchtenplein, 4, 1020, Brussels, Belgium. patrick.honore@chu-brugmann.be.

Sebastien Redant (S)

ICU Department, Brugmann University Hospital, Centre Hospitalier Universitaire Brugmann, Place Van Gehuchtenplein, 4, 1020, Brussels, Belgium.

Thomas Datzmann (T)

Universitätsklinik Ulm, Ulm, Germany.

Classifications MeSH